Budesonide-Glycopyrronium-Formoterol Fumarate Dihydrate (Breztri Aerosphere)

Abstract

CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. This review assesses budesonide-glycopyrronium (as bromide)-formoterol fumarate dihydrate, pressurized inhalation aerosol for oral inhalation (Breztri Aerosphere) (182 mcg/8.2 mcg/5.8 mcg per metered actuation). Indication: Indicated for the long-term maintenance treatment to reduce exacerbations of COPD and treat airflow obstruction to relieve symptoms in patients with COPD, including chronic bronchitis and/or emphysema, who are not adequately treated by a combination of an ICS-LABA or a combination of a LAMA-LABA.